Latest Period
Q1 2026
Security Snapshot
Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (IRON) Institutional Ownership
CUSIP: 254604101
13F Institutional Holders and Ownership History from Q4 2022 to Q1 2026
Institutions Reporting
201
Shares (Excl. Options)
41,790,891
Price
$63.94
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- IRON on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 41,790,891
- Total 13F value
- $2,667,822,262
- Portfolio coverage rank
- 0.01%
- Share change
- +3,426,875
- Value change
- +$184,842,449
- Number of holders
- 201
- Shares outstanding
- 37,778,373
- SEC-reported price per share
- $70.03
- Insider filing price
- $70.03
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- IRON - Disc Medicine, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 254604101.
- 201 institutions reported positions in Q1 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 195 to 201 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $3,040,405,091 to $2,667,822,262.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 201 institutions filings for Q1 2026.
Security key
254604101
Latest holder period
Q1 2026
13F holders
201
13D/G owners
9
CIK / CUSIP context first
Open Q1 2026 holders
IRON full holder history
Disc Medicine, Inc. SEC filings
Disc Medicine, Inc. company facts
Disc Medicine, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 254604101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
IRON
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 14% | +16% | $324,265,066 | +$45,337,554 | 4,907,159 | +16% | FMR LLC | 30 Sep 2025 |
| AI DMI LLC | 8% | -25% | $199,459,837 | -$49,166,626 | 3,018,460 | -20% | AI DMI LLC | 20 Oct 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 5.9% | $177,001,530 | 2,228,924 | RA Capital Management, L.P. | 30 Dec 2025 | |||
| ORBIMED ADVISORS LLC | 4.5% | $73,382,798 | 1,556,369 | ORBIMED ADVISORS LLC | 10 Mar 2025 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 4.1% | -39% | $79,996,547 | -$50,911,307 | 1,432,090 | -39% | Wellington Management Group LLP | 30 Jun 2025 |
| Paradigm Biocapital Advisors LP | 3.5% | $57,097,283 | 1,210,971 | Paradigm BioCapital Advisors LP | 31 Mar 2025 | |||
| Frazier Life Sciences Public Fund, L.P. | 3% | $57,339,676 | 1,026,489 | Frazier Life Sciences Public Fund, L.P. | 30 Jun 2025 | |||
| Bain Capital Life Sciences Opportunities III, LP | 3.3% | $46,372,025 | 983,500 | Bain Capital Life Sciences Opportunities III, LP | 31 Dec 2024 | |||
| Atlas Venture Fund X, L.P. | 2.2% | -30% | $73,469,638 | -$24,517,376 | 813,167 | -25% | Atlas Venture Fund X, L.P. | 12 Dec 2025 |
As of 31 Mar 2026, 201 institutional investors reported holding 41,790,891 shares of Disc Medicine, Inc. - Common Stock, $0.0001 par value per share (IRON). This represents 111% of the company’s total 37,778,373 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
86%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 5,586,894 | +2.5% | 0.02% | $357,226,003 |
| RA CAPITAL MANAGEMENT, L.P. | 6.5% | 2,450,221 | +24% | 1.7% | $156,667,131 |
| BlackRock, Inc. | 6% | 2,273,831 | -0.05% | 0% | $145,388,755 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.6% | 1,735,376 | +14% | 0.02% | $110,959,941 |
| STATE STREET CORP | 4.5% | 1,698,244 | +43% | 0% | $108,585,721 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.1% | 1,549,350 | -8.8% | 0.01% | $99,067,000 |
| Atlas Venture Life Science Advisors, LLC | 4% | 1,513,875 | 0% | 12% | $96,797,168 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 1,375,430 | 0% | 0% | $87,944,994 |
| JPMORGAN CHASE & CO | 3.6% | 1,371,480 | -13% | 0.01% | $83,358,592 |
| Frazier Life Sciences Management, L.P. | 3.6% | 1,354,852 | +7.5% | 2.2% | $86,629,237 |
| TCG Crossover Management, LLC | 3.6% | 1,341,862 | 2.5% | $85,798,656 | |
| BVF INC/IL | 3.4% | 1,272,312 | +96% | 2.6% | $81,351,629 |
| ORBIMED ADVISORS LLC | 2.8% | 1,067,550 | 0% | 1.5% | $68,259,147 |
| Siren, L.L.C. | 2.6% | 988,401 | 0% | 1.8% | $63,198,360 |
| Woodline Partners LP | 2.5% | 958,281 | +0.05% | 0.23% | $61,272,487 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 744,222 | +8.7% | 0% | $47,595,151 |
| Vestal Point Capital, LP | 1.9% | 700,000 | -4.8% | 1.3% | $44,758,000 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.7% | 657,000 | +29% | 0.5% | $42,008,580 |
| GOLDMAN SACHS GROUP INC | 1.7% | 639,842 | -15% | 0.01% | $40,911,498 |
| JENNISON ASSOCIATES LLC | 1.6% | 610,382 | +15% | 0.03% | $39,027,825 |
| Logos Global Management LP | 1.5% | 560,000 | +9.8% | 1.8% | $35,806,400 |
| Assenagon Asset Management S.A. | 1.4% | 546,247 | +53% | 0.06% | $34,927,033 |
| ARMISTICE CAPITAL, LLC | 1.4% | 536,000 | +7.3% | 1.1% | $34,271,840 |
| Bellevue Group AG | 1.2% | 459,314 | 0.7% | $29,368,537 | |
| Saturn V Capital Management LP | 1.2% | 449,926 | +51% | 5.2% | $28,768,268 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
14
Latest
Q1 2026
Rows shown
1-14 of 14
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 41,790,891 | $2,667,822,262 | +$184,842,449 | $63.94 | 201 |
| 2025 Q4 | 38,292,771 | $3,040,405,091 | +$327,723,771 | $79.41 | 195 |
| 2025 Q3 | 34,174,573 | $2,258,188,476 | +$16,098,753 | $66.08 | 164 |
| 2025 Q2 | 34,069,403 | $1,804,405,782 | +$52,373,227 | $52.96 | 148 |
| 2025 Q1 | 33,154,047 | $1,649,828,469 | +$313,979,403 | $49.64 | 155 |
| 2024 Q4 | 26,576,603 | $1,684,756,023 | -$53,215,124 | $63.40 | 151 |
| 2024 Q3 | 27,309,249 | $1,342,089,295 | -$26,632,908 | $49.14 | 130 |
| 2024 Q2 | 27,576,793 | $1,242,993,864 | +$212,594,407 | $45.07 | 119 |
| 2024 Q1 | 22,155,328 | $1,379,374,874 | +$124,372,681 | $62.26 | 125 |
| 2023 Q4 | 20,197,167 | $1,166,592,879 | +$18,737,189 | $57.76 | 111 |
| 2023 Q3 | 19,879,838 | $933,957,855 | +$42,877,645 | $46.98 | 90 |
| 2023 Q2 | 19,115,397 | $848,710,699 | +$223,083,623 | $44.40 | 89 |
| 2023 Q1 | 14,612,435 | $309,637,635 | +$77,103,451 | $21.19 | 45 |
| 2022 Q4 | 10,800,037 | $214,639,221 | +$202,496,221 | $19.89 | 30 |